The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Beam Therapeutics Inc shares valued at $1,347,050 were sold by Ciaramella Giuseppe on Nov 06 ’24. At $26.36 per share, Ciaramella Giuseppe sold 51,110 shares. The insider’s holdings dropped to 109,150 shares worth approximately $2.57 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Ciaramella Giuseppe sold 51,110 shares, netting a total of over 1,342,752 in proceeds. Following the sale of shares at $26.27 each, the insider now holds 160,260 shares.
Before that, Giuseppe Ciaramella had added 102,220 shares to its account. In a trade valued at $2,519,723, the Officer bought Beam Therapeutics Inc shares for $24.65 each.
As published in a research note from Leerink Partners on November 06, 2024, Beam Therapeutics Inc [BEAM] has been rated up from a Market perform to an Outperform and the price target has been revised to $39 from $27. Analysts at Scotiabank started covering the stock with ‘”a Sector outperform”‘ outlook in a report released in mid October. As of July 23, 2024, H.C. Wainwright has initiated its “Buy” rating for BEAM. Earlier on January 29, 2024, JP Morgan upgraded its rating. Their new recommendation was “an Overweight” for BEAM stock which previously was a “a Neutral”.
Analyzing BEAM Stock Performance
During the last five days, there has been a drop of approximately -10.38%. Over the course of the year, Beam Therapeutics Inc shares have dropped approximately -13.37%. Shares of the company reached a 52-week high of $49.50 on 02/27/24 and a 52-week low of $20.84 on 04/25/24. A 50-day SMA is recorded $24.54, while a 200-day SMA reached $26.76. Nevertheless, trading volume fell to 1.01 million shares from 1.21 million shares the previous day.
Support And Resistance Levels for Beam Therapeutics Inc (BEAM)
According to the 24-hour chart, there is a support level at 23.04, which, if violated, would cause prices to drop to 22.49. In the upper region, resistance lies at 24.42. The next price resistance is at 25.25. RSI (Relative Strength Index) is 45.28 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.38, which suggests the price will decrease in the coming days. Percent R is at 80.42%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
